79th Annual Report of the Company
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.1 pts less than Nifty Microcap 250 and 1.8 pts less than its Plastic Products - Industrial peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Caprihans India Ltd (formerly Bilcare Research India Ltd) filed its 79th Annual Report for FY25. Revenue from operations rose modestly to Rs. 767.56 Cr from Rs. 722.12 Cr in FY24, a growth of about 6.3%. However, losses deepened, with Profit After Tax at negative Rs. 61.80 Cr versus negative Rs. 51.62 Cr the previous year. EBITDA remained deeply negative at minus Rs. 72.26 Cr, and the company recorded exceptional items of Rs. 6.05 Cr. No dividend was recommended, and management cited working capital constraints and severe cash flow issues. The company relocated its Thane plant to Ambernath, made a Rs. 19.84 Cr provision for doubtful recovery from Anax Industries, and promoter Bilcare Ltd infused capital via 48 lakh warrants (Rs. 96 Cr), of which 14.9 lakh were converted into equity shares. A new subsidiary, Bilcare Research GmbH, was set up in Germany.
Shareholders face a second straight year of losses, no dividend, and growing cash flow stress, though the promoter capital infusion via warrants provides near-term liquidity support. The stock may remain under pressure until the company returns to profitability.